Small Molecule Antagonists Of The Pro-Survival Protein Mcl-1
Direct inhibition of the MCL-1 proteinSmall molecule inhibitor
Therapeutic approach to activate the apoptosis pathway, potentially leading to cancer cell deathPotentially used as a combination therapy, or as a monotherapy
UCLA Researchers in the Department Chemistry & Biochemistry have developed novel small molecules that bind MCL-1, which in turn promotes the activation of the apoptosis pathway, resulting in cancer cell death.
2017066747
State Of Development Successful demonstration in vitro binding of recombinant protein Background Multiple cancer types, including chronic lymphocytic leukemia (CML) have been shown to overexpress signaling proteins involved the inhibition of apoptosis, including BCL-2 and MCL-1.This feature makes these proteins ideal targets for cancer therapeutics.Currently, there is one small molecule that has been FDA approved that targets this signaling pathway, binding to BCL-2.However, 60% of patients each year are resistant to this treatment, highlighting the necessity of targeting other proteins within this pathway, such as MCL-1. Related Materials Tech ID/UC Case 27303/2014-387-0 Related Cases 2014-387-0
USA
